Von Hippel-Lindau methylation status in patients with multiple myeloma: A potential predictive factor for the development of boneDisease

Clinical Lymphoma and Myeloma

Volumn 9, Issue 3, 2009, Pages 239-242

  Hatzimichael, Eleftheria ^a   Dranitsaris, George ^b   Dasoula, Aggeliki ^a   Benetatos, Leonidas ^a   Stebbing, Justin ^c   Crook, Tim ^c   Bourantas, Konstantinos ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Bone disease; CpG island; HIF 1 ; Plasma cell neoplasia; VHL gene

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MELPHALAN; THALIDOMIDE; VASCULOTROPIN; VINCRISTINE; VON HIPPEL LINDAU PROTEIN; VHL PROTEIN, HUMAN;

AGED; ANGIOGENESIS; ARTICLE; BONE DEVELOPMENT; BONE DISEASE; BONE DYSPLASIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CELL SURVIVAL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; CPG ISLAND; DEATH; DISEASE COURSE; DISEASE MARKER; DOWN REGULATION; FEMALE; GENE SILENCING; HAZARD RATIO; HEPATOSPLENOMEGALY; HUMAN; LYMPHADENOPATHY; MALE; MICROENVIRONMENT; MORTALITY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PREDICTION; PROSPECTIVE STUDY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METHYLATION; RISK; STRESS; THROMBOCYTOPENIA; BONE MARROW CELL; CHEMISTRY; DNA METHYLATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; METHYLATION; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PROMOTER REGION;

AGED; BONE DISEASES; BONE MARROW CELLS; CPG ISLANDS; DNA METHYLATION; FEMALE; HUMANS; MALE; METHYLATION; MIDDLE AGED; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PROMOTER REGIONS, GENETIC; TRANSCRIPTION, GENETIC; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 69149109764     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.047     Document Type: Article

References (19)

1. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005; 23:6333-8.
2. Ohh M. Ubiquitin pathway in VHL cancer syndrome. Neoplasia 2006; 8:623-9.
3. Semenza GL. Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE. 2007; 2007:cm8
4. Asosingh K, De Raeve H, de Ridder M, et al. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. Haematologica 2005; 90:810-7.
5. Krishnamachary B, Semenza GL. Analysis of hypoxia-inducible factor 1 alpha expression and its effects on invasion and metastasis. Oxygen Biol Hypoxia 2007; 435:347-54.
6. Quintero M, Mackenzie N, Brennan PA. Hypoxia-inducible factor 1 (HIF-1) in cancer. Eur J Surg Oncol 2004; 30:465-8.
7. Dulaimi E, de Caceres II, Uzzo RG, et al. Promoter hypermethylation profile of kidney cancer. Clin Cancer Res 2004; 10:3972-9.
8. Xu XL, Yu J, Zhang HY, et al. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J Gastroenterol 2004; 10:3441-54.
9. Benetatos L, Dasoula A, Syed N, et al. Methylation analysis of the von Hippel-Lindau gene in acute myeloid leukaemia and myelodysplastic syndromes. Leukemia 2008; 22:1293-5.
10. Chim CS, Wong SY, Kwong YL. Aberrant gene promoter methylation in acute promyelocytic leukaemia: profile and prognostic significance. Br J Haematol 2003; 122:571-8.
11. Chim CS, Kwong YL, Fung TK, et al. Methylation profiling in multiple myeloma. Leuk Res 2004; 28:379-85.
12. Mitsiades CS, Mitsiades NS, Munshi NC, et al. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer 2006; 42:1564-73.
13. An JB, Rettig MB. Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity. Mol Cell Biol 2005; 25:7546-56.
14. Asosingh K, De Raeve H, Van Riet I, et al. Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis. Blood 2003; 101:3136-41.
15. Asosingh K, De Raeve H, Menu E, et al. Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity. Blood 2004; 103:3131-7.
16. An JB, Fisher M, Rettig MB. VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappa B-dependent mechanism. Oncogene 2005; 24:1563-70.
17. Roccaro AM, Hideshima T, Raje N, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006; 66:184-91.
18. Kaluz S, Kaluzova M, Stanbridge EJ. Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha C-terminal activation domain. Mol Cell Biol 2006; 26:5895-907.
19. Shin DH, Chun YS, Lee DS, et al. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood 2008; 111:3131-6.